Medivir - TMC435 will be evaluated in a phase II combination study with daclatasvir (BMS 790052) for HCV genotype-1 patients
Huddinge, Sweden - Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMY). TMC435, a once daily NS3/4A protease inhibitor (PI) for the treatment of genotype-1 chronic hepatitis C virus (HCV) infection will be investigated in combination with Bristol-Myers Squibb´s investigational NS5A replication complex inhibitor, daclatasvir. Charlotte Edenius,